Sahajanand Medical Technologies IPO Analysis: Should You Apply? GMP, Review & Details

Sahajanand Medical Technologies is a MAINBOARD IPO in the Hospital sector. The issue price band is ₹327.0–₹344.0 per share. Issue size is ₹475.48 crore. Current GMP is +4.94% over the issue price (unofficial, subject to change).

Sahajanand Medical Technologies IPO — Key Details

Company Overview

Sahajanand Medical Technologies Ltd. is a medical device company established in 2001, specializing in Class III and Class C/D devices for vascular and structural heart interventions. The company gained recognition as the first globally to receive CE certification for a drug-eluting stent with a biodegradable polymer. Its product range includes coronary stents, advanced technologies like Transcatheter Aortic Valve Implantation, and various other medical devices. Sahajanand operates R&D centers in India and Thailand and has a strong intellectual property portfolio with numerous patents. The company has a global presence, distributing products in over 76 countries.

Financial Performance

For the period ending June 30, 2026, total income was ₹354.33 Cr, a significant decrease from ₹1,218.73 Cr for the year ending March 31, 2026. This decline is notable as the June figure is a 9-month figure, not a full year, so isn't directly comparable. Prior to that, total income was ₹1,035.96 Cr for the year ending March 31, 2025, indicating a downward trend in revenue in the most recent period. Profit after tax for the period ending June 30, 2026, was ₹15.09 Cr, a sharp decline from ₹69.08 Cr for the year ending March 31, 2026. This is again a 9-month figure and cannot be directly compared to the full-year figure. In the previous year, March 31, 2025, profit after tax was ₹25.15 Cr, showing a decrease in profitability in the latest reported period.

Objects of the Issue

The IPO aims to raise ₹475.48 Cr, with the issue price set at ₹344.0 per share. The lot size is 43 shares, requiring a minimum investment of ₹14,792.

Understanding Grey Market Premium (GMP)

The Grey Market Premium (GMP) indicates the expected listing price of an IPO based on unofficial trading before it officially lists. A positive GMP suggests that the stock may list at a higher price than the issue price, while a negative GMP indicates the opposite.

Subscription Status

As of October 19, 2026, the IPO has received strong interest, with a total subscription of 14.21 times. The institutional segment saw the highest demand, with Qualified Institutional Buyers (QIBs) subscribing 34.7 times the shares offered. Non-Institutional Investors (NIIs) and Retail Investors also showed significant interest, subscribing 14.64 times and 3.04 times, respectively.

Peer Comparison

• Sahajanand Medical: P/E 50.59
• Laxmi Dental: P/E 36.35
• Poly Medicure: P/E 51.4

IPO Timeline

The IPO opens for subscription on October 15, 2026, and closes on October 19, 2026. Allotment of shares will be finalized by October 21, 2026, with the listing expected on October 23, 2026.

Should You Apply for Sahajanand Medical Technologies IPO?

Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy and risk tolerance. It's essential to consider the company's financial health, market position, and growth potential.

Those who prefer stable investments with lower risk or who are not comfortable with the inherent uncertainties of the IPO market may want to avoid investing in this IPO.

This is general risk-profile education, not a personal recommendation to apply or avoid this specific IPO — TopFund is not a SEBI-registered investment adviser.

Listing Day Risks

Listing gains can vary widely and are influenced by market conditions, investor sentiment, and the company's performance. While a positive GMP may suggest potential gains, there are no guarantees, and investors should be prepared for the possibility of losses.

Trending Searches

Disclaimer: This is educational content, not investment advice. GMP is an unofficial grey-market indicator, unregulated and never guaranteed. TopFund is not a SEBI-registered investment adviser — please do your own research or consult a qualified adviser before applying to any IPO.